Smith Group Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Smith Group Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,278	Closed	-$554K	–	535
2015 Q3	$554K	Sell	8,278 -3	-0%	-$245	0.02%	191
2015 Q2	$806K	Buy	8,281 +2,245	+37%	+$214K	0.03%	181
2015 Q1	$564K	Buy	+6,036	New	+$514K	0.02%	193
2013 Q4	–	Sell	-21,001	Closed	-$626K	–	453
2013 Q3	$626K	Buy	21,001 +2,590	+14%	+$90.6K	0.03%	186
2013 Q2	$976K	Buy	+18,411	New	+$807K	0.04%	182

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

LIM

Lagoda Investment Management New York $182M AUM 58.16% 1-Year Est. Return

Smith Group Asset Management's MACK Position: Q4 2015 in Review

Smith Group Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 8,278 shares — an estimated $554K sold.

Smith Group Asset Management first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $976K in Q2 2013. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

Smith Group Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
Smith Group Asset Management sold 8,278 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $554K.
Smith Group Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
Smith Group Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $976K in Q2 2013.
139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.